NCT06545500View on ClinicalTrials.gov

A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD

PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

August 16, 2024

Primary Completion Date

January 2, 2025

Study Completion Date

January 8, 2025

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG

Glycopyrrolate (85 μg)

Administered by a standard jet nebulizer, twice daily for 7 consecutive days

DRUG

Glycopyrrolate (42.5 μg)

Administered by a standard jet nebulizer, twice daily for 7 consecutive days

DRUG

Glycopyrrolate (14 μg)

Administered by a standard jet nebulizer, twice daily for 7 consecutive days

DRUG

Placebo

Administered by a standard jet nebulizer, twice daily for 7 consecutive days

Trial Locations (7)

28277

American Health Research Inc, Charlotte

29303

Velocity Clinical Research - Spartanburg, Spartanburg

29379

Velocity Clinical Research - Union, Union

29615

Velocity Clinical Research - Greenville, Greenville

33606

Clinical Research of West Florida Inc - Tampa, Tampa

33765

Clinical Research of West Florida Inc - Clearwater, Clearwater

63301

Midwest Chest Consultants PC, Saint Charles

All Listed Sponsors
lead

Verona Pharma plc

INDUSTRY

NCT06545500 - A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD | Biotech Hunter | Biotech Hunter